3SBio Inc. in 1 story
The narratives 1530.HK currently appears in, with its side and exposure in each.
Bull side
1 story- China Becomes Pharma's Global R&D Engine
1530.HK in “China Becomes Pharma's Global R&D Engine”
FadingExposure: not rated yetWestern drugmakers are licensing clinically validated Chinese molecules rather than relying solely on expensive in-house discovery.
Its clinically validated PD-1/VEGF bispecific pipeline and major licensing agreement with Pfizer exemplify multinational demand for China-origin oncology assets.
Bear side
0 storiesNo bear-side stories for 1530.HK yet.